| Business Summary | | Lexicon
Genetics,
Inc.
is
a
drug
discovery
company
that
uses
gene
knockout
technology
to
define
the
functions
of
genes
for
the
discovery
of
pharmaceutical
products.
The
Company
uses
its
gene-targeting
and
gene-trapping
technologies
to
generate
alterations
that
selectively
disrupt
or
conditionally
regulate
the
function
of
the
targeted
gene.
As
of
December
31,
2000,
Lexicon's
OmniBank
library
contained
gene
knockout
clones
for
more
than
40%
of
all
genes
in
the
mammalian
genome.
The
LexVision
technology
platform
of
the
Company
enables
it
to
assess
the
phenotypic
consequences,
or
function
in
a
living
mammal,
of
the
knocked-out
gene
across
a
variety
of
parameters
relevant
to
human
disease,
including
cancer,
cardiovascular
disease,
immune
disorders,
neurological
disease,
diabetes
and
obesity. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | LEXG
is
a
genomics
company
using
gene
trapping
technology
to
discover
thousands
of
genes
and
to
expand
its
OmniBank
library
of
tens
of
thousands
of
knockout
mouse
clones
for
drug
discovery.
For
the
six
months
ended
6/30/01,
revenues
increased
15%
to
$6.8
million.
Net
loss
increased
5%
to
$17.9
million.
Revenues
reflect
increased
subscription
and
license
fees.
Net
loss
reflects
increased
R&D
expenses
due
to
higher
personnel
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| C. Thomas Caskey, M.D., 62 Chairman | -- | -- | Arthur Sands, M.D., Ph.D., 39 Pres,
CEO, Director | $525K | -- | Julia Gregory, 48 Exec.
VP, CFO | 272K | $439K | Jeffrey Wade, J.D., 36 Exec.
VP, Gen. Counsel | 259K | 29K | James Piggott, Ph.D., 46 Sr.
VP of Pharmaceutical Biology | 249K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|